A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 70
Healthy Volunteers: f
View:
• Prostate cancer with \>3 years of LHRH agonist therapy.
• Age ≥70 years.
• ECOG performance status ≤2
• Baseline testosterone of \< 20 ng/ml
• No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
• Ability to understand and sign informed consent.
Locations
United States
Illinois
The University of Illinois at Chicago (UIC)
RECRUITING
Chicago
UChicago Medicine Comprehensive Cancer Center
NOT_YET_RECRUITING
Chicago
Contact Information
Primary
Clinical Trials Intake
cancerclinicaltrials@bsd.uchicago.edu
1-855-702-8222
Time Frame
Start Date: 2026-06
Estimated Completion Date: 2027-06
Participants
Target number of participants: 155
Treatments
Experimental: discontinuation of LHRH agonist therapy in elderly prostate cancer patients
Related Therapeutic Areas
Sponsors
Leads: University of Chicago